Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

French group synthesizes new imino-sugar derivatives

Feb. 12, 2013

Synageva BioPharma begins phase III ARISE trial

Feb. 12, 2013

Bristol-Myers Squibb patents new Y4 receptor agonists

Feb. 12, 2013

Novo Nordisk receives complete response letter for Tresiba and Ryzodeg

Feb. 11, 2013

Glucokinase plus insulin genetic therapy cures diabetes in dogs

Feb. 11, 2013

AstraZeneca patents new MCH1 receptor antagonists

Feb. 11, 2013

Novel DPP IV inhibitors synthesized at Boehringer Ingelheim

Feb. 11, 2013

Xenon receives Glybera approval milestone payment

Feb. 6, 2013

The Medicines Company and Alnylam to develop therapeutics for hypercholesterolemia

Feb. 5, 2013

Lyxumia approved in E.U. as first once-daily prandial GLP-1 receptor agonist

Feb. 4, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...